Celltrion Chairman Jung-Jin Seo and CEO Jin-Seok Seo participated in the 22nd Morgan Stanley Global Healthcare Conference in New York on September 6th, presenting the group's competitive strengths and growth strategies.

At the 22nd annual Morgan Stanley Global Healthcare Conference, Celltrion outlined its future vision. The event, hosted by Morgan Stanley, brings together biotech companies and global institutional investors. This year, over 400 healthcare companies and investors participated in company discussions and presentations.

Celltrion conducted both a presentation and a panel discussion. CEO Jin-Seok Seo presented *"From Pioneer to Innovator,"* where he highlighted Celltrion’s new drug pipeline, biosimilar developments, and future growth plans. The company aims to expand its pipeline to include antibody-drug conjugates (ADCs) and multispecific antibodies, with several "best-in-class" candidates expected to be unveiled between this year and next.

Celltrion is fast-tracking three ADC and three multispecific antibody drugs, aiming for commercialization by 2029. Two ADC candidates showing the most promise will be unveiled this year, with clinical trials set to begin in 2024.

In the biosimilar market, Celltrion emphasized that only companies with a solid portfolio, strong supply chain, and multi-product strategy will survive. The company plans to secure approvals for 11 products by 2025, expanding to 22 by 2030. Celltrion also aims to expand treatment areas beyond autoimmune diseases into asthma, ophthalmology, and metabolic bone diseases, while leveraging a multi-product strategy to strengthen negotiating power with Pharmacy Benefit Managers (PBMs).

During a panel discussion, Chairman Jung-Jin Seo shared Celltrion’s growth outlook for 2024 and vision for new ventures. He highlighted the successful U.S. launch of Zymfentra, which secured listing agreements with major PBMs within six months. A media campaign, including TV and social media ads, is planned for September. Seo expressed confidence in achieving $250 million in annual sales for Zymfentra and forecasted $5 billion in total sales by 2025 if the product performs as expected.

Looking ahead, Celltrion plans to secure new production facilities, either in South Korea or internationally, by the end of 2024. These facilities will support both biosimilar production and Contract Development and Manufacturing Organization (CDMO) activities. Seo also indicated the company's readiness to make corporate investments that align with its goal of becoming a global pharmaceutical leader.